Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs
about
Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids SignalingCrystallographic study of FABP5 as an intracellular endocannabinoid transporterAcyl-coenzyme A-binding protein regulates Beta-oxidation required for growth and survival of non-small cell lung cancer.Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41Fatty-acid-binding protein inhibition produces analgesic effects through peripheral and central mechanisms.Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.Pharmacophore-based similarity scoring for DOCKInhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia.Involvement of fatty acid amide hydrolase and fatty acid binding protein 5 in the uptake of anandamide by cell lines with different levels of fatty acid amide hydrolase expression: a pharmacological study.Hydrogen-bonded His93 as a sensitive probe for identifying inhibitors of the endocannabinoid transport protein FABP7.Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation.CRABP-II- and FABP5-independent responsiveness of human glioblastoma cells to all-trans retinoic acidDOCK 6: Impact of new features and current docking performance.Fatty acid binding protein deletion suppresses inflammatory pain through endocannabinoid/N-acylethanolamine-dependent mechanisms.Examination of the Addictive and Behavioral Properties of Fatty Acid-Binding Protein Inhibitor SBFI26.Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr ResidueNuclear Factor Erythroid 2-Related Factor 2 Deficiency Results in Amplification of the Liver Fat-Lowering Effect of Estrogen.Genetic and neuroendocrine regulation of the postpartum brain.A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs).More surprises lying ahead. The endocannabinoids keep us guessing.Strategies for lead discovery: application of footprint similarity targeting HIVgp41.Implementation of the Hungarian algorithm to account for ligand symmetry and similarity in structure-based designTransport of endocannabinoids across the plasma membrane and within the cell.FABP-1 gene ablation impacts brain endocannabinoid system in male mice.Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets.A Mixed-Ligand Chiral Rhodium(II) Catalyst Enables the Enantioselective Total Synthesis of Piperarborenine B.RNA-Seq analysis of enteroendocrine cells reveals a role for FABP5 in the control of GIP secretion.Cyclobutane-1,3-Diacid (CBDA): A Semi-Rigid Building Block Prepared by [2+2] Photocyclization for Polymeric Materials.The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites.Fatty acid binding protein 5 controls microsomal prostaglandin E synthase 1 (mPGES-1) induction during inflammation.Δ9-Tetrahydrocannabinol Induces Endocannabinoid Accumulation in Mouse Hepatocytes: Antagonism by Fabp1 Gene Ablation.The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.Fatty-acid-binding protein 5 controls retrograde endocannabinoid signaling at central glutamate synapses[2+2] Photocycloaddition of Cinnamates in Flow and Development of a Thiourea Catalyst.
P2860
Q26777055-8FBB99D6-BADB-43E6-A45E-6BF84E09F9BEQ27681752-0F569B43-869F-4B4B-98D7-3310C85623DBQ30407718-F538AA7D-FEC5-4293-807F-F194E7047714Q33590499-4732D75A-EDC5-4B3E-9C10-45DE480957EDQ33610506-01B136D9-8048-4D88-A789-C4641D542D39Q33761619-88D7229A-573D-45A3-9385-17943624A548Q34461976-9A9BD050-78E5-4E4E-B275-F8F36B3A407CQ34538205-09908A3A-AFB8-4562-A2F0-5E093EABA902Q35013407-65FD534D-057E-4CAF-9451-528DA4605CB8Q35140182-9073B2EF-823C-4528-8E0F-3C7FC1FFDE12Q35216071-D81C0C77-5E96-4BF1-A45C-029CB656F925Q35217789-18EA1969-B71A-44A4-BCA3-464438DC200DQ35642600-E47A1FB2-A64B-43EE-9D77-0B9509BF2B60Q35742427-B21EC58B-0CDC-423E-8035-EFF5885CA5E3Q35748554-E6F8D3D3-CF51-4ABE-9A33-61C4FCC0AFF4Q36001928-BC10CFF1-A57E-4122-81AD-6B9CA84E105DQ36764791-B043AED3-4A58-4541-AF94-961AD54C2C3EQ37008862-6CD6E5FD-1413-4468-AD16-CC5D0A4E6EE2Q37062567-26DAE04B-781A-4661-8425-7D764BEF38C5Q37270454-49CDBA73-63E0-473D-86E3-42F96D1239F6Q37335452-F70E319C-024A-407D-B5E0-2991544E8C2AQ37373721-C95BF725-3702-4B83-8448-19A2F6AA931CQ37552860-BEB479E9-0B78-4229-8DAB-E174FE66896FQ37644156-CEE65733-EC5F-44A1-9911-AE63912DB072Q38084704-6714B235-F1A3-470F-AB51-AD17F4A3E9F9Q39775282-059FC46C-DF85-4545-8308-B6D7C9EC9F8CQ41931663-DC87180B-627A-44CA-953E-EBE358C6AB02Q42113959-C59C60EC-F792-44EF-8B59-4DFC269EF8FAQ42289792-94CEE8C5-433E-4183-9E1F-CE3A38EA9212Q42652451-E6D2151B-1685-44BB-BA50-B92C594D2930Q47794981-5F2F84DF-7886-4655-97B2-88E6F7C3C727Q50026568-761D3F68-5BDF-4ABC-A4C1-742C7126975DQ50134192-CD279399-F362-4E72-A891-E0C6DB39B611Q50142905-3562F738-013F-41C7-AFA4-EA509710F439Q52159627-83DB2056-71EE-4F6A-8A5A-EF31CA50EEF6Q53209060-8C3E04D9-5142-4958-9DB8-8A73AA2E4911
P2860
Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@ast
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@en
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@en-gb
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@nl
type
label
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@ast
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@en
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@en-gb
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@nl
altLabel
Targeting Fatty Acid Binding P ...... ory and Anti-Nociceptive Drugs
@en
prefLabel
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@ast
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@en
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@en-gb
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Targeting fatty acid binding p ...... ory and anti-nociceptive drugs
@en
P2093
Brian P Ralph
Dale G Deutsch
Robert C Rizzo
Samir Haj-Dahmane
William T Berger
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0050968
P407
P577
2012-01-01T00:00:00Z